{"id":"NCT00365352","sponsor":"XenoPort, Inc.","briefTitle":"XP13512 vs. Placebo in Patients With Restless Legs Syndrome.","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2006-08-17","resultsPosted":"2011-05-11","lastUpdate":"2013-07-22"},"enrollment":325,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Restless Legs Syndrome"],"interventions":[{"type":"DRUG","name":"XP13512 600MG","otherNames":["GSK1838262","Gabapentin Enacarbil"]},{"type":"DRUG","name":"XP13512 1200MG","otherNames":["GSK1838262","Gabapentin Enacarbil"]},{"type":"DRUG","name":"PLACEBO","otherNames":[]}],"arms":[{"label":"XP13512 600MG","type":"EXPERIMENTAL"},{"label":"XP13512 1200MG","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).","primaryOutcome":{"measure":"Change From Baseline in IRLS Rating Scale Total Score at Week 12 Using Last Observation Carried Forward (LOCF)","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-9.8,"sd":7.69},{"arm":"GEn (XP13512/GSK1838262) 1200 mg","deltaMin":-13,"sd":9.12}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0015"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27288210","27067343","26788345","21677899","21527006"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":96},"commonTop":["Somnolence","Dizziness","Headache","Nasopharyngitis","Dry Mouth"]}}